Sex-related differences in treatment outcomes of chronic hepatitis C with direct-acting antivirals

Figure 1 Sustained virologic response at 12 weeks post-treatment by age group and sex. Color gradients indicate the magnitude of response success, and each cell shows the precise sustained virologic response at 12 weeks post-treatment percentage for clarity. SVR12: Sustained virologic response at 12 weeks post-treatment.

Figure 2 Mild and severe adverse event rates by sex and age group for direct-acting antivirals-treated hepatitis C virus patients. Mild adverse event (AE) represent any reported event, while severe AEs comprise liver transplant, hepatocellular carcinoma, and decompensated liver cirrhosis. AE: Adverse event.

Figure 3 Fibrosis progression trends by sex and age group.